Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Hope you had a restful, tasty holiday. In today’s Readout, we discuss former FDA Commissioner Scott Gottlieb publicly speaking out against the nomination of Robert F. Kennedy Jr. for HHS secretary, we see there’s a massive talent gap in radiopharmaceuticals, and more.
The need-to-know this morning
- Cytokinetics said the FDA accepted its application seeking approval for the heart disease drug aficamten. The FDA decision date is Sept. 26, and at this time, the agency has no plans to schedule an advisory committee meeting.
- Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC Therapeutics, the companies said Monday.
Radiopharma needs way more talent
There’s been considerable interest in radiopharmaceuticals lately. These cutting-edge therapies use radioactive isotopes to precisely target cancer cells. But the field’s facing a severe talent shortage, both on the development side and also in the medical facilities that administer the treatments, STAT’s Allison DeAngelis reports. It takes specialized skills to administer these radioactive medicines, and relatively few professionals possess them.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
